AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Methods to Predict Efficacy of Cancer Stem Cell Targeted Therapy (SD2012-084)

Technology Benefits

• Compatible with nanofluidic proteomic assays, which enable automated and more sensitive detection of isoform variants• Novel biomarkers of response in validated primary cancer stem cell populations• Can confirm mechanism of action and synergistic activity (i.e. JAK2 and BCR-ABL inhibitors)• Uses both protein and confirmatory nucleic acid readouts to decrease the likelihood of false negative and false positive results.

Technology Application

The pattern of alternatively spliced JAK2 and STAT5A RNA isoforms as well as their protein products can be used to: measure the effectiveness of a therapy targeting leukemic stem cells (LSC);predict or monitor which patients will be most responsive to targeted agents; assess the resistance, or relative resistance, of self-renewing LSC; andDistinguish leukemic progenitors from their normal counterparts.

Detailed Technology Description

UC researchers have found that the extent of JAK2 and STAT5A phosphorylation as well as the RNA isoform patterns indicate the extent of response to selective JAK2 inhibition and can also be used to inform the clinician whether this therapeutic approach is likely to succeed.

Supplementary Information

Inventor: Safavy, Ahmad
Priority Number: US6191290B1
IPC Current: A61K004748
US Class: 549510 | 549511 | 514449
Assignee Applicant: UAB Research Foundation,Birmingham
Title: Taxane derivatives for targeted therapy of cancer
Usefulness: Taxane derivatives for targeted therapy of cancer
Summary: (I) are useful in the treatment of breast and ovarian cancer, as well as skin, lung, head and neck carcinomas (claimed).
Novelty: New soluble tumor-directed paclitaxel derivatives are useful in the treatment of breast and ovarian cancer, skin, lung, head and neck carcinomas

Industry

Disease Diagnostic/Treatment

Sub Group

Cancer/Tumor

Application No.

9611330

Others

State Of Development

The invention has been validated in humanized murine models of CML (LSC engrafted RAG2-/-c-/- mice) using a JAK2 inhibitor (SAR302503), which is currently in clinical trials. Nanoproteomic analysis confirmed that phospho-JAK2 and phospho-STAT5A distinguished leukemic progenitors from their normal counterparts and analysis of isoforms has identified useful RNA biomarkers. Interestingly, synergistic inhibition of self-renewal isoforms was found for combination treatment using SAR302503 and dasatinib (a BCR-ABL inhibitor).

Intellectual Property Info

Worldwide rights available for licensure (See WO2013036867)

Related Materials

Fan, Alice C., et al., (2009) Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clincal specimens, Nature Medicine, 15( 5): 566-571
O'Neill, Roger A., et al., (2006) Isoelectric focusing technology quantifies protein signaling in 25 cells, PNAS, 103(44): 16153-16158
Jiang, Q. et al., (2012) ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia, Proc Natl Acad Sci U S A., (3):1041-6
also see: http://hem-onc.ucsd.edu/faculty/jamieson.shtml

Tech ID/UC Case

22588/2012-037-2

Related Cases

2012-037-2, 2012-084-0

Country/Region

USA

For more information, please click Here